BD Issues FY 2022 ESG Report, Highlights Notable Progress in Energy and Waste Reduction, Health Care Access and Diversity

Company Expands its ESG Focus Areas to Include Advancing Health Equity in Under-Resourced Communities 

FRANKLIN LAKES, N.J., July 20, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its Fiscal Year 2022 Environmental, Social and Governance (ESG) Report that details ongoing efforts that impact company health, human health, community health and planet health.

"We all have a responsibility for taking action to advance sustainability efforts and ESG issues relevant to our businesses, and at BD, we're making meaningful progress addressing our impacts on the environment and the communities where we live and work, from minimizing our environmental footprint, to empowering a diverse and inclusive workforce, and advancing health equity and access to health care in under-resourced areas of the world," said Tom Polen, chairman, CEO and president of BD. "We take great pride in the role we've played throughout our history in creating a healthier world, and our global associates continue to demonstrate the resilience and growth mindset necessary to catalyze this positive change and make a meaningful impact for our company, planet, communities and the people we serve."

The report includes performance measurements and progress made toward the company's 2030+ ESG goals, focusing on key areas where the company looks to create meaningful, measurable change over the next decade. Top highlights and achievements from this year's report include: 

• Climate Change – BD reduced its scope 1 and 2 greenhouse gas (GHG) emissions by 10 percent in FY 2022 (from a FY 2019 baseline), and made progress toward its 2040 carbon neutral goal by increasing the number of sites using renewable electricity to 31. Of these sites, 17 are using 100 percent renewable electricity, five sites are using partial renewable electricity, and nine sites are utilizing on-site renewables.  
  
  
• Product Impact – BD launched the Sustainable Medical Technology Institute and initiated partnerships with health systems, regulated waste management companies and recyclers in the United States, Brazil, Denmark, Australia and New Zealand to explore circular economy solutions for managing BD products at end of life.
  
  
• Responsible Supply Chain –BD significantly increased the opportunities open to small and diverse businesses, achieving a 75 percent increase year-over-year in the number of certified, small and diverse-owned suppliers within the company's supply chain. In this time, BD spent more than $600 million with these suppliers, ultimately totaling $1.1 billion in positive economic impact.
  
  
• Healthy Workforce and Communities – BD achieved a year-over-year increase in ethnic diversity at the associate, management and executive levels in the U.S., and an increase in global gender diversity at the management and executive levels. BD and the BD Foundation donated more than $22.5 million in cash and products worldwide to eligible non-profit organizations to support resilient communities and expand health care access and equity. The company also increased focus on advancing health equity in under-resourced areas of the world, furthering its longstanding commitment to expanding access and building capacity of health systems in developed and developing communities.
  
  
• Transparency -- For its sixth consecutive year, BD was recognized by The Center for Political Accountability (CPA) with a rating of 100 percent on its 2022 corporate political disclosure and accountability index. As part of the company's cybersecurity governance, BD achieved ISO/IEC 27001:2022 certification in FY 2022, which demonstrates a steadfastness to maintaining world-class cybersecurity standards.

Maureen Mazurek, chief EHS and sustainability officer at BD said, "We are making great strides on our journey to build and maintain a sustainable, resilient business model that positions BD and its stakeholders for success. With the dedication of our leaders, the passion of our associates, and partnerships across the value chain, we have reduced greenhouse gas emissions by 10 percent, increased the number of locations using renewables, piloted recycling programs around the world, and completed our baseline assessment for scope 3 emissions. We are proud of the work we've accomplished thus far but know there is more to be done as we work toward accomplishing our 2030+ ESG goals."

For more information about BD's 2030+ ESG goals and to view the company's full FY 2022 ESG Report, visit BD.com. Learn more about awards and recognition for BD's ESG impact on the BD Newsroom.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo. 

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws regarding BD's business, strategy, goals, commitments and objectives. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed, projected, anticipated or implied in such statements. All statements, other than statements of historical facts, may be forward-looking statements. Some forward-looking statements may be identified by the use of words such as "plan," "expect," "believe," "intend," "will," "may," "anticipate," estimate," "target," and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance and strategy for growth, future product development, regulatory approvals, competitive position, sustainability initiatives and expenditures. Readers should not place undue reliance on forward-looking statements. Forward-looking statements are, and will be, based on management's then-current views and assumptions regarding future events, developments and operating performance, and speak only as of their dates.

Statements regarding BD's goals, commitments and objectives may include statistics or metrics that are based on estimates and assumptions under developing standards that may change in the future. Such goals and commitments are not intended to be promises or guarantees and actual results may differ, possibly materially. It is not possible to predict or identify all of these risks and uncertainties, many of which are beyond BD's control, including without limitation, challenges relating to economic, competitive, governmental, and technological factors affecting BD's operations, markets, and products, and other factors listed in BD's 2022 Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. BD expressly disclaims any undertaking to update or revise any forward-looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation.

SOURCE BD (Becton, Dickinson and Company)